trastuzumab deruxtecan for her2-low metastatic breast cancer | dr. jitendra pahlajani
Published 1 month ago • 48 plays • Length 25:11Download video MP4
Download video MP3
Similar videos
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
5:59
trastuzumab deruxtecan for the treatment of her2 breast cancer
-
11:46
dr renu mishra | transform the journey for your her2 breast cancer patients
-
5:57
phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer patients
-
20:48
dr mukesh | redefining the standard of care for postmenopausal hr her2 abc
-
59:29
first-line endocrine-based therapy for patients with hr , her2-negative metastatic breast cancer
-
3:31
her2-low mbc patients report preserved qol with trastuzumab deruxtecan
-
1:05
efficacy of trastuzumab deruxtecan in her2-low metastatic breast cancer
-
5:09
trastuzumab deruxtecan shows benefit across her2 metastatic breast cancer subgroups
-
1:29
tuxedo-1: trastuzumab deruxtecan for the treatment of her2-positive breast cancer brain metastases
-
24:47
dr srikant tiwari | recent developments in the management of er her2 metastatic breast cancer
-
10:26
dr sai vivek | management of her2 early breast cancer
-
30:03
dr piyush mehta | advances in the management of localized her2 positive breast cancer
-
16:24
dr randeep singh | neo adjuvant ct for hr her2 breast cancer
-
28:19
panel discussion dr vamshi krihsna |sequencing agents for hr ve mbc in clinical practice perspective
-
1:17
comment: phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer pts